Proteomics

Dataset Information

0

Proteomics quality and standard: from a regulatory perspective


ABSTRACT: Cultured mouse lymphoma cells were lysed with a buffer containing 50 mM Tris-HCl (pH 8.0) and 8 M Urea with or without a protease inhibitor cocktail (Sigma). The lysates were desalted and digested with sequencing-grade modified trypsin (Promega). Different amounts of peptides were analyzed using nanoflow RPLC-MS/MS on a linear ion trap mass spectrometer (LTQ XL, Thermo Electron, San Jose, CA). The raw MS/MS data were searched using SEQUEST running under BioWorks (Rev. 3.3.1 SP1) (Thermo Electron, San Jose, CA) against a mouse IPI proteome database (Version 3.62) downloaded from the European Bioinformatics Institute (EBI) (http://www.ebi.ac.uk). For the SEQUEST analysis, the peptide mass tolerance was set as 2.0 Da and the fragment ion tolerance was 1.0 Da. A tryptic enzyme restriction with a maximum of two internal missed cleavage sites was used. The Xcorr versus charge state values were filtered at Xcorr ≥ 1.7 for [M+H]1+ ions, ≥ 2.5 for [M+2H]2+ ions, ≥ 3.2 for [M+3H]3+ ions, and P ≤ 0.01 and ΔCn ≥ 0.08 were applied for identification of all fully tryptic peptides. The peptide ion chromatogram was extracted using a minimum intensity threshold of 100, mass tolerance of 2.0 amu and smoothing point of 5, and the area of the extracted ion chromatographic (XIC) peak was integrated and calculated using the PepQuan module in Bioworks (Thermo Electron, San Jose, CA).

INSTRUMENT(S): LTQ

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Li-Rong Yu  

LAB HEAD: Li-Rong Yu

PROVIDER: PXD000334 | Pride | 2022-02-15

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
A10_PI_Minus.RAW Raw
A10_PI_Minus.srf Other
B10_PI_Minus.RAW Raw
B10_PI_Minus.srf Other
C9_PI_Minus.RAW Raw
Items per page:
1 - 5 of 42
altmetric image

Publications

Proteomics quality and standard: from a regulatory perspective.

Gu Qiang Q   Yu Li-Rong LR  

Journal of proteomics 20131204


Proteomics has emerged as a rapidly expanding field dealing with large-scale protein analyses. It is anticipated that proteomics data will be increasingly submitted to the U.S. Food and Drug Administration (FDA) for biomarker qualification or in conjunction with applications for the approval of drugs, medical devices, and other FDA-regulated consumer products. To date, however, no established guideline has been available regarding the generation, submission and assessment of the quality of prote  ...[more]

Similar Datasets

2014-03-26 | PXD000090 | Pride
2018-11-09 | MSV000083126 | MassIVE
2022-05-20 | PXD031198 | Pride
2023-10-24 | PXD038133 | Pride
2018-11-09 | MSV000083126 | GNPS
2014-10-15 | PXD000078 | Pride
2013-04-09 | PXD000113 | Pride
2014-03-02 | PXD000226 | Pride
2019-11-12 | PXD000353 | Pride
2013-07-26 | PXD000225 | Pride